Tuesday 19 March 2024
 
»
 
»
Story

CorMedix .... developing and commercialising therapeutic
products.

CorMedix signs Mideast sales distribution deal

NEW JERSEY, December 24, 2014

CorMedix, a pharmaceutical company focused on developing and commercialising therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, has signed a Middle East sales/distribution deal for lead product Neutronlin with Arabian Trade House in Saudi Arabia.

Saudi Arabia, which is the largest of the six Gulf Cooperation Council (GCC) countries, has approximately 13,000 patients on hemodialysis; with central venous catheter (CVC) usage rates are as high as 40 per cent. 

In Saudi Arabian intensive care units (ICU), there are an estimated 1.6 million patients per year on catheters and an estimated 3,000 oncology patients with catheters.

CorMedix's Neutrolin is a formulation of taurolidine, citrate and heparin with 1,000 u/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis, and biofilm to keep catheter's operating safely and efficiently by optimising catheter blood flow while minimising infections and biofilm formation.

Randy Milby, chief executive officer, said: ”We are pleased to make Neutrolin available in Saudi Arabia to help the many patients with catheters in the dialysis setting who need new options for the prevention of infection and thrombosis.

"This agreement extends our commercial reach into the Middle East and is creating a new revenue stream for the company." - TradeArabia News Service




Tags: Saudi | Sales | Distribution | agreement |

More Industry, Logistics & Shipping Stories

calendarCalendar of Events

Ads